EVs as Potential New Therapeutic Tool/Target in Gastrointestinal Cancer and HCC

被引:19
|
作者
Slomka, Artur [1 ]
Mocan, Tudor [2 ]
Wang, Bingduo [3 ]
Nenu, Iuliana [2 ]
Urban, Sabine K. [3 ]
Gonzalez-Carmona, Maria A. [3 ]
Schmidt-Wolf, Ingo G. H. [4 ]
Lukacs-Kornek, Veronika [5 ]
Strassburg, Christian P. [3 ]
Sparchez, Zeno [2 ]
Kornek, Miroslaw [3 ]
机构
[1] Nicolaus Copernicus Univ Torun, Ludwik Rydygier Coll Med Bydgoszcz, Dept Pathophysiol, PL-85067 Bydgoszcz, Poland
[2] Univ Med & Pharm, Octavian Fodor Inst Gastroenterol & Hepatol, Iuliu Hatieganu, Cluj Napoca 400162, Romania
[3] Rhein Friedrich Wilhelms Univ, Dept Internal Med 1, Univ Hosp, D-53127 Bonn, Germany
[4] Rhein Friedrich Wilhelms Univ, Univ Hosp, Ctr Integrated Oncol CIO, Dept Integrated Oncol, D-53127 Bonn, Germany
[5] Rhein Friedrich Wilhelms Univ, Univ Hosp, Inst Expt Immunol, D-53127 Bonn, Germany
关键词
HCC; gastrointestinal and liver cancers; extracellular vesicles; exosomes; microvesicles; ectosomes; biomarker; drug resistance; MESENCHYMAL STEM-CELLS; EXTRACELLULAR VESICLES EXOSOMES; HEPATOCELLULAR-CARCINOMA CELLS; PROMOTE TUMOR-GROWTH; COLORECTAL-CANCER; GASTRIC-CANCER; MEDIATED TRANSFER; IN-VITRO; T-CELLS; SERUM;
D O I
10.3390/cancers12103019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Extracellular vesicles (EVs)- cell derived organic, nano-sized particles that are more then only cell dust. Nowadays, EVs are a scientifically accepted novel route for cells, including tumour cells, to communicate and influence their host, orchestrating cellular processes from simple tumour growth to complex mechanism of tumour tolerance. Here we show the current understanding of those EVs in gastrointestinal cancer and hepatocellular carcinoma (HCC). The review emphasizes the potential of EVs as a new therapeutic tool and drug target. It critically evaluates their role, in an informative manner using cutting edge, current publications. Many of the cited work are regarded as milestones in the EV field of research drawing a promising perspective for future EV studies. For more than a decade, extracellular vesicles (EVs) have been in focus of science. Once thought to be an efficient way to eliminate undesirable cell content, EVs are now well-accepted as being an important alternative to cytokines and chemokines in cell-to-cell communication route. With their cargos, mainly consisting of functional proteins, lipids and nucleic acids, they can activate signalling cascades and thus change the phenotype of recipient cells at local and systemic levels. Their substantial role as modulators of various physiological and pathological processes is acknowledged. Importantly, more and more evidence arises that EVs play a pivotal role in many stages of carcinogenesis. Via EV-mediated communication, tumour cells can manipulate cells from host immune system or from the tumour microenvironment, and, ultimately, they promote tumour progression and modulate host immunity towards tumour's favour. Additionally, the role of EVs in modulating resistance to pharmacological and radiological therapy of many cancer types has become evident lately. Our understanding of EV biology and their role in cancer promotion and drug resistance has evolved considerably in recent years. In this review, we specifically discuss the current knowledge on the association between EVs and gastrointestinal (GI) and liver cancers, including their potential for diagnosis and treatment.
引用
收藏
页码:1 / 28
页数:28
相关论文
共 50 条
  • [1] MicroRNAs as a New Potential Therapeutic Opportunity in Gastrointestinal Cancer
    Boni, V.
    Bandres, E.
    Zarate, R.
    Colucci, G.
    Maiello, E.
    Garcia-Foncillas, J.
    ONCOLOGY, 2009, 77 : 75 - 89
  • [2] CDT1 is a Potential Therapeutic Target for the Progression of NAFLD to HCC and the Exacerbation of Cancer
    He, Xingyu
    Ma, Jun
    Yan, Xue
    Yang, Xiangyu
    Wang, Ping
    Zhang, Lijie
    Li, Na
    Shi, Zheng
    CURRENT GENOMICS, 2024,
  • [3] Expression of MN antigen in urologic cancer: Potential tool as a therapeutic target
    Uemura, H
    Nakagawa, Y
    Hirao, Y
    Okajima, E
    Yoshikawa, K
    Oosterwijk, E
    AKTUELLE UROLOGIE, 2000, 31 : 52 - 54
  • [4] A new therapeutic target for HCV-related HCC
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (04) : 422 - 422
  • [5] Survivin is a Potential New Therapeutic Target in the Treatment of Pancreatic Cancer
    Ly, Q. P.
    Howell, G.
    Mendick, M.
    Murari, C.
    Laschanzky, S.
    Brattain, M.
    PANCREAS, 2015, 44 (08) : 1394 - 1395
  • [7] Survivin is a Potential New Therapeutic Target in the Treatment of Pancreatic Cancer
    Ly, Q. P.
    Person, J. J.
    Teggart, C. A.
    Mathiesen, M. R.
    Howell, G. M.
    Brattain, M. G.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S154 - S154
  • [8] Serine racemase is a potential new therapeutic target for colon cancer
    Ohshima, Kenji
    Ikeda, Jun-ichiro
    Morii, Eiichi
    CANCER SCIENCE, 2018, 109 : 329 - 329
  • [9] Telomerase: a potential therapeutic target for cancer
    Fletcher, TM
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2005, 9 (03) : 457 - 469
  • [10] Ghrelin: A potential therapeutic target for cancer
    Nikolopoulos, Dimitrios
    Theocharis, Stamatis
    Kouraklis, Gregory
    REGULATORY PEPTIDES, 2010, 163 (1-3) : 7 - 17